Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
T | 0.700 | CausalMutation | CLINVAR | V559A and N822I double KIT mutant melanoma with predictable response to imatinib? | 21159146 | 2011 |
|||||||
|
|
A | 0.700 | CausalMutation | CLINVAR | ||||||||||
|
|
C | 0.700 | GeneticVariation | CLINVAR | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | 23444215 | 2013 |
|||||||
|
|
T | 0.700 | GeneticVariation | CLINVAR | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | 23444215 | 2013 |
|||||||
|
|
T | 0.700 | CausalMutation | CLINVAR | ||||||||||
|
|
G | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||||||
|
|
T | 0.700 | GeneticVariation | CLINVAR | Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | 19718025 | 2009 |
|||||||
|
|
C | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||||||
|
|
A | 0.700 | GeneticVariation | CLINVAR | Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. | 24132921 | 2013 |
|||||||
|
|
G | 0.700 | GeneticVariation | CLINVAR | C-RAF mutations confer resistance to RAF inhibitors. | 23737487 | 2013 |
|||||||
|
|
A | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||||||
|
|
C | 0.700 | GeneticVariation | CLINVAR | ||||||||||
|
|
A | 0.700 | GeneticVariation | CLINVAR | Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | 19718025 | 2009 |
|||||||
|
|
A | 0.700 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.700 | GeneticVariation | CLINVAR | Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | 19718025 | 2009 |
|||||||
|
|
T | 0.700 | CausalMutation | CLINVAR | ||||||||||
|
|
T | 0.700 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |
|||||||
|
|
G | 0.700 | CausalMutation | CLINVAR | Determinants of BRAF mutations in primary melanomas. | 14679157 | 2003 |
|||||||
|
|
T | 0.700 | CausalMutation | CLINVAR | Determinants of BRAF mutations in primary melanomas. | 14679157 | 2003 |
|||||||
|
|
G | 0.700 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244. | 19915144 | 2009 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. | 22197931 | 2011 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. | 21107320 | 2010 |
|||||||
|
|
G | 0.700 | GeneticVariation | CLINVAR | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. | 23569304 | 2013 |